ClinicalTrials.gg
RecruitingNCT06275061COMESUpdated Feb 23, 2024

Chinese Obesity and MEtabolic Surgery Database (COMES Database)

An observational study in Obesity, Metabolic Surgery and Bariatric Surgery, sponsored by Jinan University Guangzhou. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-02-23.

Sponsored by Jinan University Guangzhou · Observational

How we know

From the registry’s dates

  • Started May 2020; still recruiting 6 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 603 studies in Obesity with a site in China — 223 open to participants now, 284 under way, 67 of them phase 3. Obesity · China.

Planned enrollment
Largest of 99
1,000,000 · median 320
Started
2020
with 21 others
Observational
99 of 603
37 open now
Primary completion
2030-12
later than 275 of 282 live
Registered
249th of 603
by date

Among the 603 studies in Obesity with a site in China, this one has the largest planned enrollment of the 99 observational ones that give a count, is one of 22 that started in 2020, is one of 99 observational ones, reaches primary completion later than 275 of the 282 other live ones, and was the 249th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

223 of the 603 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

218 more — sign in →

All 223 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

The purpose of the Chinese Obesity and MEtabolic Surgery Database (COMES Database) is to collect data and examine the long-term effects of metabolic and bariatric surgery on obesity and metabolic disorders in the Chinese population.

Read the detailed description

COMES Database is a prospective managed national database to collect data and examine the long-term effects of metabolic and bariatric surgery on obesity and metabolic disorders in the Chinese population.

03

Conditions studied

  • Obesity
  • Metabolic Surgery
  • Bariatric Surgery
  • Weight Loss

Keywords

  • Obesity
  • Metabolic Surgery
  • Bariatric Surgery
  • Weight Loss
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients diagnosed as obesity undergoing metabolic and bariatric surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed as obesity undergoing metabolic and bariatric surgery.

Exclusion criteria

Exclusion Criteria:

  • Patients treated by non-surgical modalities.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000,000 participants (estimated)
Target follow-up
30 Years
Patient registry
Yes

Groups and cohorts

  • Metabolic and Bariatric Surgery

    Metabolic and bariatric surgery is weight loss surgery that results in weight loss and resolution of metabolic disorders.

    Procedure: Metabolic and Bariatric Surgery

Interventions

  • ProcedureMetabolic and Bariatric Surgery

    Metabolic and bariatric surgery is weight loss surgery that results in weight loss and resolution of metabolic disorders.

06

What researchers measure

Primary outcomes

  1. Excess weight loss effect of metabolic and bariatric surgery after 1 year

    Percent excess weight loss (%EWL) = \[(initial weight)-(post-op weight)\]/\[(initial weight)-(ideal weight)\]

    Time frame: 1 year

Secondary outcomes

  1. Excess weight loss effect of metabolic and bariatric surgery in long-term follow-ups

    Percent excess weight loss (%EWL) = \[(initial weight)-(post-op weight)\]/\[(initial weight)-(ideal weight)\]

    Time frame: 3 years

  2. Excess weight loss effect of metabolic and bariatric surgery in long-term follow-ups

    Percent excess weight loss (%EWL) = \[(initial weight)-(post-op weight)\]/\[(initial weight)-(ideal weight)\]

    Time frame: 5 years

  3. Excess weight loss effect of metabolic and bariatric surgery in long-term follow-ups

    Percent excess weight loss (%EWL) = \[(initial weight)-(post-op weight)\]/\[(initial weight)-(ideal weight)\]

    Time frame: 10 years

  4. Glycemic control effect of metabolic and bariatric surgery after 1 year

    Change of HbA1c levels

    Time frame: 1 year

  5. Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups

    Change of HbA1c levels

    Time frame: 3 years

  6. Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups

    Change of HbA1c levels

    Time frame: 5 years

  7. Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups

    Change of HbA1c levels

    Time frame: 10 years

  8. Glycemic control effect of metabolic and bariatric surgery after 1 year

    Change of blood glucose levels

    Time frame: 1 year

  9. Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups

    Change of blood glucose levels

    Time frame: 3 years

  10. Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups

    Change of blood glucose levels

    Time frame: 5 years

  11. Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups

    Change of blood glucose levels

    Time frame: 10 years

  12. Glycemic control effect of metabolic and bariatric surgery after 1 year

    Change of C-peptide levels

    Time frame: 1 year

  13. Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups

    Change of C-peptide levels

    Time frame: 3 years

  14. Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups

    Change of C-peptide levels

    Time frame: 5 years

  15. Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups

    Change of C-peptide levels

    Time frame: 10 years

  16. Glycemic control effect of metabolic and bariatric surgery after 1 year

    Change of insulin levels

    Time frame: 1 year

  17. Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups

    Change of insulin levels

    Time frame: 3 years

  18. Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups

    Change of insulin levels

    Time frame: 5 years

  19. Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups

    Change of insulin levels

    Time frame: 10 years

Other outcomes

  1. Adverse events rate of metabolic and bariatric surgery

    Surgical safety by 30 days follow-up according to guideline

    Time frame: 30 days after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2020 (actual). Primary completion is estimated for Dec 2030, 127 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 127 months is above that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2024
First posted
Feb 23, 2024
StartActual
May 1, 2020
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2040
Last update
Feb 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06275061
Lead sponsor
Jinan University Guangzhou
Collaborators
Chinese Obesity and Metabolic Surgery Collaborative
Responsible party
Wah Yang, MD (Principal Investigator, Jinan University Guangzhou) — Principal investigator
First posted
Feb 23, 2024
Start date
May 1, 2020
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2040 (estimated)
Last update
Feb 23, 2024

Study contacts

Wah Yang, MD
Contact
yangwah@qq.com
+8615920373823
Cunchuan Wang, MD, PhD
study chair · First Affiliated Hospital of Jinan University
Wah Yang, MD
study director · First Affiliated Hospital of Jinan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion